Cargando…

Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice

SIMPLE SUMMARY: Cancer-of-unknown-primary-origin (CUP) is challenging to diagnose and treat, and little is known about its diagnostic work-up, treatment, and outcomes in routine healthcare. We examined data from elderly patients (at least 66 years old) diagnosed with CUP in real-world US clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mileshkin, Linda, Bochtler, Tilmann, Gatta, Gemma, Kurzrock, Razelle, Beringer, Andreas, Müller-Ohldach, Mathis, Surinach, Andy, Perret, Camille, Thomas, Marlene, Gondos, Adam, Krämer, Alwin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221531/ https://www.ncbi.nlm.nih.gov/pubmed/35740574 http://dx.doi.org/10.3390/cancers14122905

Ejemplares similares

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
por: Pauli, Chantal, et al.
Publicado: (2021)

Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
por: Bochtler, Tilmann, et al.
Publicado: (2019)

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
por: Ross, Jeffrey S., et al.
Publicado: (2020)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
por: Sadetsky, Natalia, et al.
Publicado: (2020)

Comparison of SEER Treatment Data With Medicare Claims
por: Noone, Anne-Michelle, et al.
Publicado: (2016)

Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset
por: Ambs, Anita, et al.
Publicado: (2008)

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
por: Pouyiourou, Maria, et al.
Publicado: (2023)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
por: Brar, Gagandeep, et al.
Publicado: (2020)

Opportunities for Personalizing Colorectal Cancer Care: An Analysis of SEER-Medicare Data
por: Rivers, Zachary T., et al.
Publicado: (2022)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
por: Wieder, Robert, et al.
Publicado: (2023)

Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia
por: Bochtler, Tilmann, et al.
Publicado: (2016)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Trends in Sociodemographic Disparities in Colorectal Cancer Staging and Survival: A SEER–Medicare Analysis
por: Liang, Peter S., et al.
Publicado: (2020)

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
por: Scarton, Lisa, et al.
Publicado: (2022)

Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis
por: Karim, Mohammad A., et al.
Publicado: (2023)

Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis
por: de Savornin Lohman, Elise, et al.
Publicado: (2022)

Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database
por: Satram-Hoang, Sacha, et al.
Publicado: (2014)

Using Pointwise Mutual Information for Breast Cancer Health Disparities Research With SEER-Medicare Claims
por: Egleston, Brian L., et al.
Publicado: (2023)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare
por: Petrick, Jessica L., et al.
Publicado: (2017)

SUN-626 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus in a Seer-Medicare Cohort
por: Thapi, Sahityasri, et al.
Publicado: (2020)

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020)

Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis
por: Ades, Steven, et al.
Publicado: (2022)

Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study
por: Goldman, Debra A, et al.
Publicado: (2020)

Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study
por: Saris, Daniel H., et al.
Publicado: (2022)

Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD study
por: Montes de Oca, Mary Katherine, et al.
Publicado: (2023)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
por: Nazha, Bassel, et al.
Publicado: (2022)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Chemotherapy Administration during Pelvic Radiation for Cervical Cancer Patients Aged ≥55 Years in the SEER-Medicare Population
por: Kunos, Charles, et al.
Publicado: (2008)

Disparities in long-term radiographic follow-up after cystectomy for bladder cancer: Analysis of the SEER-Medicare database
por: Alanee, Shaheen, et al.
Publicado: (2016)

The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis
por: Jeon, Christie Y., et al.
Publicado: (2015)

Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare
por: Shah, Gunjan L., et al.
Publicado: (2016)

Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study
por: Shen, C., et al.
Publicado: (2018)

Hemochromatosis, Iron Overload–Related Diseases, and Pancreatic Cancer Risk in the Surveillance, Epidemiology, and End Results (SEER)-Medicare
por: Julián-Serrano, Sachelly, et al.
Publicado: (2021)

Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data
por: Ye, Qing, et al.
Publicado: (2021)

Stage II/III Rectal Cancer Post-Treatment Surveillance Patterns of Care: A SEER- Medicare Study
por: Chioreso, Catherine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b99cej11gjjn9uv8roeskvmkvn